Sugi Predict

Sugi Predict / Targets / ENPP1

ENPP1

Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 · P22413 · ENPP1 on Sugi Atlas →

51,657 patent compounds predicted against ENPP1, 26,703 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Buquineran Buquineran (SCHEMBL783795) 0.60 7/20
Datpalphas Datpalphas (SCHEMBL222923) 0.70 6/20
SCHEMBL165491 SCHEMBL165491 0.66 6/20
SCHEMBL708780 SCHEMBL708780 0.54 6/20
SCHEMBL543337 SCHEMBL543337 0.83 5/20
Adenosine Phosphate Adenosine Phosphate (SCHEMBL292320) 0.79 5/20
SCHEMBL638702 SCHEMBL638702 0.78 5/20
SCHEMBL345288 SCHEMBL345288 0.58 5/20
SCHEMBL197331 SCHEMBL197331 0.57 5/20
SCHEMBL687294 SCHEMBL687294 0.56 5/20
Chlorfenson Chlorfenson (SCHEMBL116752) 0.55 5/20
SCHEMBL205857 SCHEMBL205857 0.51 5/20
SCHEMBL664787 SCHEMBL664787 0.49 5/20
SCHEMBL687580 SCHEMBL687580 0.43 5/20
SCHEMBL158619 SCHEMBL158619 0.41 5/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL159132) 0.40 5/20
SCHEMBL195864 SCHEMBL195864 1.00 4/20
SCHEMBL195865 SCHEMBL195865 1.00 4/20
SCHEMBL375601 SCHEMBL375601 1.00 4/20
SCHEMBL375602 SCHEMBL375602 1.00 4/20

Clinical trials — most relevant to ENPP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency PHASE3RECRUITING
Alendronate Versus Denosumab in Kidney Transplant Patients PHASE2/PHASE3COMPLETED
The Prevention of Systemic Ectopic Mineralization in Pseudoxanthoma Elasticum PHASE3RECRUITING
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency PHASE3ACTIVE_NOT_RECRUITING
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE PHASE1/PHASE2COMPLETED
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency PHASE1/PHASE2COMPLETED
Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP) PHASE2WITHDRAWN
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency PHASE1RECRUITING
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients EARLY_PHASE1RECRUITING
Natural History of GACI With or Without ARHR2 or PXE nanUNKNOWN
Study of People With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2) nanCOMPLETED
PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency nanRECRUITING
Natural History Study of ENPP1 Deficiency and the Early-onset Form of ABCC6 Deficiency nanCOMPLETED
Understanding the Spectrum of ENPP1 Deficiency and Acute ABCC6 Deficiency nanCOMPLETED
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) nanCOMPLETED
Biomarker for Hypophosphatasia Disease (BioHypophos) nanWITHDRAWN
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression nanCOMPLETED
Exome Sequencing for Atypical Femoral Fractures nanCOMPLETED
Circulating miRNAs and Bone Microstructure in Adults With Hypophosphatasia nanUNKNOWN
Studying Phosphorus Metabolism nanCOMPLETED
Genetic Study of Families Affected by Paget's Disease of Bone nanCOMPLETED
United States Hypophosphatasia Molecular Research Center nanCOMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism nanNOT_YET_RECRUITING
Genetic Studies of Lysosomal Storage Disorders nanENROLLING_BY_INVITATION
Pathophysiology of Paget's Disease of Bone nanCOMPLETED
Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte nanCOMPLETED
Investigating the Genetic Basis of Pseudoexfoliation Syndrome, Angle-closure Glaucoma and Primary Open-angle Glaucoma nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a ENPP1 binder may also engage these)

ProteinNameSimilarity
Q6DYE8 — 1.000 Q6DYE8 →
P06802 — 1.000 P06802 →
ENPP3 Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 1.000 landscape →
Q924C3 — 1.000 Q924C3 →
W8E7D1 — 0.999 W8E7D1 →
P0DQQ4 — 0.998 P0DQQ4 →
P97675 — 0.997 P97675 →
J3SBP3 — 0.997 J3SBP3 →
P15396 — 0.997 P15396 →
Q5R5M5 — 0.997 Q5R5M5 →
J3SEZ3 — 0.995 J3SEZ3 →
A0A2D0TC04 — 0.994 A0A2D0TC04 →
Q64610 — 0.992 Q64610 →
Q9R1E6 — 0.992 Q9R1E6 →
ENPP2 Autotaxin 0.988 landscape →
A1A4K5 — 0.985 A1A4K5 →
Q9NY28 — 0.985 Q9NY28 →
Q8R4K8 — 0.982 Q8R4K8 →
Q52KP5 — 0.981 Q52KP5 →
Q5NDE7 — 0.980 Q5NDE7 →
A7E2Z9 — 0.979 A7E2Z9 →
Q9MYY0 — 0.978 Q9MYY0 →
A8MWY0 — 0.977 A8MWY0 →
Q5RB89 — 0.977 Q5RB89 →
Q9YHB3 — 0.977 Q9YHB3 →
P18563 — 0.977 P18563 →
MEP1A Meprin A subunit alpha 0.977 landscape →
Q6P1J0 — 0.977 Q6P1J0 →
P59511 — 0.977 P59511 →
Q9HB63 — 0.976 Q9HB63 →